Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

Key facts

Sponsor

Connecticut Children's Medical Center

Principal Investigator

Emily L Germain-Lee, MD

Connecticut Children's Medical Ctr. and Univ. of Connecticut School of Medicine

Intervention

Neurocognitive and psychosocial testing(behavioral)

Enrollment

600 enrolled

Eligibility

89 years · All sexes

Timeline

2003 – 2030

Study locations (1)

• Connecticut Children's Medical Center, Hartford, Connecticut, United States

Collaborators

Johns Hopkins University · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · UConn Health · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Albright hereditary osteodystrophy

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT04551170
  Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
  Vanderbilt University Medical Center
• ACTIVE NOT RECRUITINGPHASE2NCT03029429
  Theophylline Treatment for Pseudohypoparathyroidism
  Vanderbilt University Medical Center

See all trials for Albright hereditary osteodystrophy →